Neurology Archives - Page 6 of 11

A multicenter, randomized, double-blind, placebo-controlled study of the efficacy, tolerability, and safety of celecoxib oral solution (ELYXYB) in acute treatment of episodic migraine with or without aura

Authors: R B Lipton, S Munjal, S J Tepper, C Iaconangelo, D Serrano Published: Journal of Pain Research, 2021 View publication Background Safe, effective, oral therapies are needed for acute treatment of...

An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia

Authors: M A Piena, N Houwing, C W Kraan, X Wang, H Waters, R A Duffy, S Mallikaarjun, C Bennison Published: PharmacoEconomics, 2021 View publication Introduction Schizophrenia is a chronic mental disorder...

A three month interim analysis of fingolimod treatment adherence for relapsing remitting Multiple Sclerosis in the UK: The Patient Reported Outcomes with Fingolimod in local experience (PROFILE) study

Authors: N Adlard, J Watson, C Bottomley, M Kroes Published: Value in health, 2018 View publication Objectives The PROFILE study measured patient reported outcomes (PROs) in the real world in fingolimod-treated patients...

Health utilities associated with treatment-resistant depression in UK patients and their caregivers

Authors: T Denee, C Kerr, M Desai, J Eva, S Rathod Published: 2020 View publication This study assessed major depressive disorder (MDD) and treatment-resistant depression (TRD) patient and carer health utilities in...

Discussing multiple sclerosis (MS) progression with patients: experiences of UK healthcare professionals from the SPECTRUM project

Authors: M Duddy, C Wilkinson, K Rhys, S Medhurst Published: 2020 View publication Abstract Background: Receiving a diagnosis of secondary progressive multiple sclerosis (SPMS) can have a significant psychological impact on patients....

A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis

Authors: C Bottomley, A Lloyd, G Bennett, N Adlard Published: Journal of medical economics, 2017 View publication Aims The recent licensing of Disease Modifying Treatments (DMTs) for Multiple Sclerosis (MS) has increased...

A three month interim analysis of Treatment satisfaction with Fingolimod in patients with relapsing remitting multiple sclerosis in the UK: the Patient Reported Outcomes with Fingolimod in local Experience (PROFILE) study

Authors: Adlard N, Brisbane F, Watson J, Bishop-Bailey A, Kroes M Published: Value in Health, 2017 View publication Objectives The PROFILE study measured patient reported outcomes (PROs) in the real world in...

Maintaining adherence programme: evaluation of an innovative service model

Authors: L Lewis, C O’Keeffe, I Smyth, J Mallalieu, L Baldock, S Oliver Published: BJPsych Bulletin, 2016 View publication Aims and Method The Maintaining Adherence Programme (MAP) is a new model of...

A three month interim analysis of quality of life in patients with relapsing remitting multiple sclerosis in the UK: the patient reported outcomes with fingolimod in local experience (PROFILE) study

Authors: Nick Adlard, Fiona Brisbane, Jane Watson, Catherine Bottomley, Michel Kroes Published: 2017 View publication

News